Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
2. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol
3. Bms 512148
4. Bms-512148
5. Bms512148
6. Dapagliflozin
7. Farxiga
8. Forxiga
1. 960404-48-2
2. Dapagliflozin Propanediol Monohydrate
3. Dapagliflozin Propanediol Hydrate
4. Farxiga
5. Dapagliflozin ((2s)-1,2-propanediol, Hydrate)
6. Bms-512148-05
7. Dapagliflozin S-propylene Glycol Monohydrate
8. Dapagliflozin Propylene Glycolate Hydrate
9. Chebi:85079
10. Dapagliflozin Propanediol [usan]
11. Dapagliflozin Mixture With Propylene Glycol, Hydrate
12. 887k2391vh
13. (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2s)-propane-1,2-diol;hydrate
14. Dapagliflozin [usan:inn]
15. Dapagliflozin Propylene Glycol Hydrate
16. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol Compound With (s)-propane-1,2-diol (1:1) Hydrate
17. D-glucitol, 1,5-anhydro-1-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1s)-, Compd. With (2s)-1,2-propanediol, Hydrate (1:1:1)
18. Unii-887k2391vh
19. Dapagliflozin Propylene Glycolate Hydrate [jan]
20. Dapagliflozin (s)-propylene Glycol Hydrate
21. Chembl2103802
22. Dtxsid00914678
23. Ex-a2824
24. Dapagliflozin Propylene Glycol
25. Hy-10450a
26. Mfcd28167768
27. S5566
28. Akos027250601
29. Ccg-269711
30. Ac-29230
31. As-64915
32. Dapagliflozin (2s)-1,2-propanediol Hydrate
33. F20667
34. Bms-512148 (2s)-1,2-propanediol, Hydrate
35. Dapagliflozin (2s)-1,2-propanediol Monohydrate
36. Xigduo Component Dapagliflozin Propanediol
37. A900162
38. Dapagliflozin Propanediol Component Of Xigduo
39. Dapagliflozin Propanediol Monohydrate [who-dd]
40. Q27158320
41. Dapagliflozin Propanediol Monohydrate [ema Epar]
42. Dapagliflozin Compound With (2s)-1,2-propanediol Hydrate
43. Dapagliflozin Compound With (2s)-1,2-propanediol Hydrate [mi]
44. (2s)-propane-1,2-diol (2s,3r,4r,5s,6r)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol Hydrate
45. (2s)-propane-1,2-diol--(1s)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-d-glucitol--water (1/1/1)
46. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro- 2h-pyran-3,4,5-triol, (2s)-propane-1,2-diol (1:1) Monohydrate
47. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol (s)-propane-1,2-diol Hydrate
48. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol, (2s)-propane-1,2-diol (1:1) Monohydrate
49. 1700615-13-9
| Molecular Weight | 503.0 g/mol |
|---|---|
| Molecular Formula | C24H35ClO9 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 502.1969604 g/mol |
| Monoisotopic Mass | 502.1969604 g/mol |
| Topological Polar Surface Area | 141 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 493 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Forxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied.
Heart failure
- Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Chronic kidney disease
- Forxiga is indicated in adults for the treatment of chronic kidney disease.
Type 2 diabetes mellitus
Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Heart failure
Edistride is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Chronic kidney disease
Edistride is indicated in adults for the treatment of chronic kidney disease.
Sodium-Glucose Transporter 2 Inhibitors
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
A10BK01
A10BK01
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Thickeners and Stabilizers
Direct Compression
Lubricants & Glidants
Co-Processed Excipients
Granulation
Rheology Modifiers
Disintegrants & Superdisintegrants
Coating Systems & Additives
Solubilizers
Controlled & Modified Release
Emulsifying Agents
Chewable & Orodispersible Aids
Film Formers & Plasticizers
Taste Masking
API Stability Enhancers
Digital Content
NEWS #PharmaBuzz
Market Place
ANALYTICAL
ABOUT THIS PAGE
99
PharmaCompass offers a list of Dapagliflozin Propanediol Monohydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dapagliflozin Propanediol Monohydrate manufacturer or Dapagliflozin Propanediol Monohydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dapagliflozin Propanediol Monohydrate manufacturer or Dapagliflozin Propanediol Monohydrate supplier.
PharmaCompass also assists you with knowing the Dapagliflozin Propanediol Monohydrate API Price utilized in the formulation of products. Dapagliflozin Propanediol Monohydrate API Price is not always fixed or binding as the Dapagliflozin Propanediol Monohydrate Price is obtained through a variety of data sources. The Dapagliflozin Propanediol Monohydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A BMS-512148-05 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BMS-512148-05, including repackagers and relabelers. The FDA regulates BMS-512148-05 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BMS-512148-05 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of BMS-512148-05 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A BMS-512148-05 supplier is an individual or a company that provides BMS-512148-05 active pharmaceutical ingredient (API) or BMS-512148-05 finished formulations upon request. The BMS-512148-05 suppliers may include BMS-512148-05 API manufacturers, exporters, distributors and traders.
click here to find a list of BMS-512148-05 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A BMS-512148-05 DMF (Drug Master File) is a document detailing the whole manufacturing process of BMS-512148-05 active pharmaceutical ingredient (API) in detail. Different forms of BMS-512148-05 DMFs exist exist since differing nations have different regulations, such as BMS-512148-05 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A BMS-512148-05 DMF submitted to regulatory agencies in the US is known as a USDMF. BMS-512148-05 USDMF includes data on BMS-512148-05's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The BMS-512148-05 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of BMS-512148-05 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a BMS-512148-05 Drug Master File in Korea (BMS-512148-05 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of BMS-512148-05. The MFDS reviews the BMS-512148-05 KDMF as part of the drug registration process and uses the information provided in the BMS-512148-05 KDMF to evaluate the safety and efficacy of the drug.
After submitting a BMS-512148-05 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their BMS-512148-05 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of BMS-512148-05 suppliers with KDMF on PharmaCompass.
A BMS-512148-05 written confirmation (BMS-512148-05 WC) is an official document issued by a regulatory agency to a BMS-512148-05 manufacturer, verifying that the manufacturing facility of a BMS-512148-05 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting BMS-512148-05 APIs or BMS-512148-05 finished pharmaceutical products to another nation, regulatory agencies frequently require a BMS-512148-05 WC (written confirmation) as part of the regulatory process.
click here to find a list of BMS-512148-05 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing BMS-512148-05 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for BMS-512148-05 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture BMS-512148-05 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain BMS-512148-05 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a BMS-512148-05 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of BMS-512148-05 suppliers with NDC on PharmaCompass.
BMS-512148-05 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of BMS-512148-05 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right BMS-512148-05 GMP manufacturer or BMS-512148-05 GMP API supplier for your needs.
A BMS-512148-05 CoA (Certificate of Analysis) is a formal document that attests to BMS-512148-05's compliance with BMS-512148-05 specifications and serves as a tool for batch-level quality control.
BMS-512148-05 CoA mostly includes findings from lab analyses of a specific batch. For each BMS-512148-05 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
BMS-512148-05 may be tested according to a variety of international standards, such as European Pharmacopoeia (BMS-512148-05 EP), BMS-512148-05 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (BMS-512148-05 USP).
